文献速递湿疹皮炎与荨麻疹银屑病与炎症性皮肤病

特应性皮炎与银屑病严重程度定义:面向生物标志物研究的跨学科视角

Defining disease severity in atopic dermatitis and psoriasis for the application to biomarker research: an interdisciplinary perspective.
PubMed 文献 · Br J Dermatol · 2024-01-01

BIOMAP联盟梳理特应性皮炎与银屑病多来源数据,将严重程度工具映射至症状、炎症活动、病程三域,提出生物标志物研究中严重程度定义与验证的推荐,以促进机制发现和临床转化。

要点

  • 严重程度应综合症状、炎症活动和病程三域评估。
  • 生物标志物研究需兼顾医生报告与患者报告指标。
  • 无单一测量能涵盖严重程度全部方面,需多指标并用。

核心结论

  • BIOMAP联盟通过跨学科梳理,提出特应性皮炎与银屑病严重程度定义应覆盖症状、炎症活动和病程三域,并据此规范生物标志物研究。

研究设计与样本

  • BIOMAP为欧洲大规模跨学科研究联盟,整合横断面与队列研究、临床试验、电子健康记录及大型人群生物样本库等多来源临床与分子数据。

主要发现

  • 研究将所有数据集的疾病严重程度工具和测量映射至症状、炎症活动和病程三个关键域,并描述变量与域间的重要相互依赖关系。

关键数值与推荐

  • 优先参考国际共识、参考标准和/或专家意见来定义更严重疾病。
  • 分析多样研究类型数据时需明确生物标志物目的与临床背景。
  • 需考虑特定时间点及随时间变化的严重程度相关候选标志物及其关系。
  • 选择严重程度测量时应考虑生物标志物开发阶段。
  • 应使用医生报告和患者报告指标并在各域中验证标志物与严重程度结局的关联。

临床怎么用

  • 在生物标志物研究中采用多域、多来源的严重程度测量,兼顾医生与患者报告,并考虑治疗等影响因素。

局限性

  • 原文未报告具体样本量、效应值或验证数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

More severe atopic dermatitis and psoriasis are associated with a higher cumulative impact on quality of life, multimorbidity and healthcare costs. Proactive, early intervention in those most at risk of severe disease may reduce this cumulative burden and modify the disease trajectory to limit progression. The lack of reliable biomarkers for this at-risk group represents a barrier to such a paradigm shift in practice. To expedite discovery and validation, the BIOMarkers in Atopic Dermatitis and Psoriasis (BIOMAP) consortium (a large-scale European, interdisciplinary research initiative) has curated clinical and molecular data across diverse study designs and sources including cross-sectional and cohort studies (small-scale studies through to large multicentre registries), clinical trials, electronic health records and large-scale population-based biobanks. We map all dataset disease severity instruments and measures to three key domains (symptoms, inflammatory activity and disease course), and describe important codependencies and relationships across variables and domains. We prioritize definitions for more severe disease with reference to international consensus, reference standards and/or expert opinion. Key factors to consider when analysing datasets across these diverse study types include explicit early consideration of biomarker purpose and clinical context, candidate biomarkers associated with disease severity at a particular point in time and over time and how they are related, taking the stage of biomarker development into account when selecting disease severity measures for analyses, and validating biomarker associations with disease severity outcomes using both physician- and patient-reported measures and across domains. The outputs from this exercise will ensure coherence and focus across the BIOMAP consortium so that mechanistic insights and biomarkers are clinically relevant, patient-centric and more generalizable to current and future research efforts. Atopic dermatitis (AD), and psoriasis are long-term skin conditions that can significantly affect people’s lives, especially when symptoms are severe. Approximately 10% of adults and 20% of children are affected by AD, while psoriasis affects around 5% of people in the UK. Both conditions are associated with debilitating physical symptoms (such as itch) and have been linked to depression and anxiety. Biomarkers are naturally occurring chemicals in the human body and have potential to enhance the longer-term management of AD and psoriasis. Currently, there are no routinely used biomarkers that can identify people who experience or will go on to develop severe AD and psoriasis. For this reason, research is under way to understand which biomarkers are linked to severity. In this study, a multidisciplinary team of skin researchers from across Europe, along with patient groups, discussed the complexities of studying severity-related biomarkers. We identified a number of severity measurement approaches and there were recommendations for future biomarker research, including (i) considering multiple measures as no single measure can encompass all aspects of severity, (ii) exploring severity measures recorded by both healthcare professionals and patients, as each may capture different aspects, and (iii) accounting for influencing factors, such as different treatment approaches, that may impact AD and psoriasis severity, which make it challenging to compare findings across studies. Overall, we anticipate that the insights gained from these discussions will increase the likelihood of biomarkers being effectively applied in real-world settings, to ultimately improve outcomes for people with AD and psoriasis.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Ramessur R, Dand N, Langan SM, et al. Defining disease severity in atopic dermatitis and psoriasis for the application to biomarker research: an interdisciplinary perspective. Br J Dermatol. 2024. PMID: 38419411. doi:10.1093/bjd/ljae080

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。